Wim Janssens

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 11 drugs with upcoming expirations

Activity

Key Events

Mar 24, 2026FDAXarelto — XARELTO

Jul 28, 2025FDASirturo — SIRTURO

Jun 17, 2025FDAXarelto — XARELTO

Jan 22, 2025FDARisperdal — RISPERDAL CONSTA

Jan 22, 2025FDARisperdal — RISPERDAL

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

33 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Regulatory

Regulatory Timeline

20237 events

FDAOct 12

Sirturo — SIRTURO

Application NDA204384

FDAApr 28

Risperdal — UZEDY

Application NDA213586 (NDA)

FDAMar 31

Prezista — PREZISTA

Application NDA202895

FDAMar 31

Prezista — PREZISTA

Application NDA021976

FDAFeb 8

Xarelto — XARELTO

Application NDA022406

FDAFeb 8

Xarelto — XARELTO

Application NDA215859

FDAJan 13

Risperdal — RYKINDO

Application NDA212849 (NDA)

20244 events

FDAJul 26

Erzofri — ERZOFRI

Application NDA216352 (NDA)

FDAJun 21

Sirturo — SIRTURO

Application NDA204384

FDAMar 29

Risperdal — RISVAN

Application NDA214835 (NDA)

FDAMar 15

Edurant Ped — EDURANT PED

Application NDA219016 (NDA)

20257 events

FDAJul 28

Sirturo — SIRTURO

Application NDA204384

FDAJun 17

Xarelto — XARELTO

Application NDA215859

FDAJun 17

Xarelto — XARELTO

Application NDA022406

FDAJan 22

Risperdal — RISPERDAL CONSTA

Application NDA021346

FDAJan 22

Risperdal — RISPERDAL

Application NDA020272

FDAJan 22

Risperdal — RISPERDAL

Application NDA021444

FDAJan 22

Risperdal — RISPERDAL

Application NDA020588

20262 events

FDAMar 24

Xarelto — XARELTO

Application NDA022406

FDAMar 24

Xarelto — XARELTO

Application NDA215859

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)